NASDAQ:UMRX - Unum Therapeutics Stock Price, Forecast & News

Unum Therapeutics trades on the NASDAQ under the ticker symbol "UMRX."

Unum Therapeutics Inc (NASDAQ:UMRX) announced its earnings results on Tuesday, November, 12th. The company reported ($0.39) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.33) by $0.07. The firm had revenue of $1.02 million for the quarter, compared to the consensus estimate of $4.41 million. Unum Therapeutics had a negative return on equity of 96.07% and a negative net margin of 388.07%. View Unum Therapeutics' Earnings History.

Unum Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Unum Therapeutics.

5 analysts have issued 1 year price objectives for Unum Therapeutics' shares. Their forecasts range from $3.00 to $18.00. On average, they anticipate Unum Therapeutics' share price to reach $10.00 in the next year. This suggests a possible upside of 1,200.6% from the stock's current price. View Analyst Price Targets for Unum Therapeutics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Unum Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Unum Therapeutics.

Media headlines about UMRX stock have been trending very negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Unum Therapeutics earned a news sentiment score of -3.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Unum Therapeutics.

Unum Therapeutics saw a decrease in short interest during the month of January. As of January 15th, there was short interest totalling 372,700 shares, a decrease of 18.6% from the December 31st total of 457,600 shares. Based on an average daily trading volume, of 310,800 shares, the short-interest ratio is presently 1.2 days. Approximately 2.9% of the company's shares are sold short. View Unum Therapeutics' Current Options Chain.

Some companies that are related to Unum Therapeutics include Synlogic (SYBX), Checkpoint Therapeutics (CKPT), Immunic (IMUX), Vaccinex (VCNX), VERONA PHARMA P/S (VRNA), Sesen Bio (SESN), Oramed Pharmaceuticals (ORMP), CV Sciences (CVSI), AVEO Pharmaceuticals (AVEO), Catalyst Biosciences (CBIO), Oncolytics Biotech (ONCY), Infinity Pharmaceuticals (INFI), Neos Therapeutics (NEOS), Elite Pharmaceuticals (ELTP) and Stealth BioTherapeutics (MITO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Unum Therapeutics investors own include SCYNEXIS (SCYX), AzurRx BioPharma (AZRX), Strongbridge Biopharma (SBBP), Inovio Pharmaceuticals (INO), Onconova Therapeutics (ONTX), Matinas BioPharma (MTNB), Acasti Pharma (ACST), KemPharm (KMPH), Vistagen Therapeutics (VTGN) and Genocea Biosciences (GNCA).

(UMRX) raised $75 million in an IPO on Thursday, March 29th 2018. The company issued 5,800,000 shares at $12.00-$14.00 per share. Morgan Stanley and Cowen served as the underwriters for the IPO and SunTrust Robinson Humphrey and Wedbush Securities were co-managers.

Unum Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (1.16%), Sectoral Asset Management Inc (0.48%), Acadian Asset Management LLC (0.40%) and Goldman Sachs Group Inc. (0.15%). Company insiders that own Unum Therapeutics stock include Liam Ratcliffe, Seth Ettenberg and Venture Fund Ix LP Atlas. View Institutional Ownership Trends for Unum Therapeutics.

UMRX stock was sold by a variety of institutional investors in the last quarter, including Sectoral Asset Management Inc and Goldman Sachs Group Inc.. View Insider Buying and Selling for Unum Therapeutics.

UMRX stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and Acadian Asset Management LLC. Company insiders that have bought Unum Therapeutics stock in the last two years include Liam Ratcliffe and Venture Fund Ix LP Atlas. View Insider Buying and Selling for Unum Therapeutics.

Shares of UMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of UMRX stock can currently be purchased for approximately $0.77.

Unum Therapeutics has a market capitalization of $22.98 million and generates $9.73 million in revenue each year. The company earns $-34,530,000.00 in net income (profit) each year or ($1.39) on an earnings per share basis. Unum Therapeutics employs 56 workers across the globe.View Additional Information About Unum Therapeutics.

The official website for Unum Therapeutics is http://www.unumrx.com/.

Unum Therapeutics' mailing address is 200 CAMBRIDGE PARK DRIVE SUITE 3100, CAMBRIDGE MA, 02140. The company can be reached via phone at 617-945-5576 or via email at [email protected]